Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 18, 2016. The document serves as a transaction notification regarding a specific corporate action involving a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It reports a single transaction detail:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of Ordinary Shares via dividend re-investment under the Company's ShareReward Plan.
- Price: £16.6373 per share.
- Volume: 54 shares.
- Date: July 14, 2016.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It solely documents a routine share acquisition by Ms. C Thomas (SVP, HR) resulting from dividend re-investment.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is a regulatory disclosure of a specific share transaction.
Investor Verification Points
- Verify the transaction date (July 14, 2016) and price (£16.6373) against market data for GSK ordinary shares on the London Stock Exchange.
- Confirm the identity of the PDMR involved (Ms. C Thomas, SVP, HR) and the nature of the plan (ShareReward Plan).
- Note that this filing does not contain financial performance data; refer to the company's Form 20-F or interim reports for financial metrics.